GPRC6A and metabolic dysfunction-associated steatotic liver disease: demonstrated that intraperitoneal injection of osteocalcin significantly protected wild-type mice from obesity and NAFLD, but not liver-specific GPRC6A knockout mice, suggesting that GPRC6A mediated the ability of osteocalcin to inhibit lipid synthesis and promote lipolysis (35).